Genzyme Genetics enhances diagnostic system:
This article was originally published in Clinica
Cambridge, Massachusetts-based Genzyme Genetics, a unit of Genzyme General, has expanded its cancer testing services by "significantly stepping up" its flow cytometry programme performed in laboratories in Santa Fe, Mexico. Dr Bruce Davis, associate director for clinical research at Maine Medical Center, will direct staff interpreting test results and providing consultation services to physicians. The company has also compiled a database to assist in the interpretation of complex cases. Physicians will have secure internet access to test results as they become available. Flow cytometry diagnoses leukaemia, lymphoma, multiple myeloma among other cancers, monitors residual levels of disease present in post-treatment patients and is used as an evaluative tool of patients whose treatment is likely to fail.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.